The anti-anginal effects of Zibotentan in patients with the Coronary Slow Flow Phenomenon (CSFP)
Phase of Trial: Phase II/III
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Zibotentan (Primary)
- Indications Cardiovascular disorders; Coronary disorders; Unstable angina pectoris
- Focus Therapeutic Use
- 22 Aug 2019 Last checked against Australian New Zealand Clinical Trials Registry record.
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.
- 12 Jan 2018 New trial record